An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy.

Genetic evidence for dilated cardiomyopathy (DCM) has expanded, with 35 high-evidence gene-disease relationships identified in the latest assessment, up from 19 five years ago.

• Why it matters: Understanding the genetic architecture of DCM is crucial for accurate diagnosis and personalized treatment, but previous gene classifications required reassessment as new evidence emerged.
• What they did: The Clinical Genome Resource expert panel reevaluated 68 genes and 72 gene-disease-MOI relationships using a semiquantitative classification framework, including 17 newly assessed genes, and classified 35 as high evidence.
• The result: This updated gene curation enhances clinical interpretation of genetic data in DCM, supporting improved diagnosis and management of patients and families affected by the disease.